Abstract

Bottomley MJ, Bezstarosti S, Hester J, Issa F, Wood KJ*, Harden PN* *contributed equally Background Malignancy is a leading cause of morbidity and death in long-term renal transplant recipients (RTR). Methods to identify RTR at increased risk may enable pre-emptive intervention to reduce cancer risk. Methods We undertook a 5-year cohort study in long-term RTR. The primary outcome was time to metastatic non-melanoma skin cancer (NMSC) or non-NMSC cancer. Immune phenotype was assessed by flow cytometry and functional analyses of peripheral blood mononuclear cells (PBMC). Gene expression was assessed by real-time PCR of whole blood or multiplexed gene expression analysis by nanoString in PBMC. Univariate and multivariate analyses were undertaken by logistic regression and Cox proportional hazard modelling. Results 117 RTR (median age: 63 years old, cumulative immunosuppression duration: 262 months) were recruited. 80 completed follow up (loss to follow-up due to death in 24). CD57 expression was assessed on circulating T cells and RTR were dichotomised based on proportion expressing CD57 (>50%, CD57hi; <50%, CD57lo). CD57hi phenotype was associated with CMV seropositivity & increasing age. CD57hi RTR were 5.1 (95% CI: 1.1-23.4) times more likely to develop malignancy after adjustment for age, immunosuppression duration, CMV serostatus and history of smoking or previous cancer. PBMC from CD57hi RTR demonstrated phenotypic features of immunosenescence and a Th1-skewed transcriptome. CD8+CD57+ T cells were able to produce inflammatory cytokines and engage in cytotoxicity, upon polyclonal stimulation. Discussion CMV-driven immunosenescence is associated with a Th1-skewed circulating immune phenotype, distinct from immune exhaustion. There is an increased predisposition to malignancy development despite an abundance of circulating, functional CD8+ T cells. The mechanism behind this is under investigation.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.